https://tickzen.app/stocks/edit/company
Editas Medicine, Inc. (EDIT) Company Profile & Information | Tickzen
Editas Medicine, Inc. (EDIT) stock is at $2.35, down 3.69%. Analyst target: $5.90 (151.1% upside). Detailed company information, business overview, management,...
editas medicinecompany profileincinformation
https://www.globenewswire.com/fr/news-release/2026/05/26/3300882/0/en/editas-medicine-presents-edit-401-preclinical-data-demonstrating-robust-reductions-in-ldl-c-lp-a-and-apob-in-non-human-primates-at-the-94th-european-atherosclerosis-society-congres.html
Editas Medicine Presents EDIT-401 Preclinical Data
Single dose of EDIT-401 achieved ~90% or greater mean reductions in LDL-C, Lp(a), and ApoB in non-human primates Data reinforce differentiated LDLR...
editas medicinepresentspreclinicaldata
https://www.fool.com/investing/2021/03/04/why-editas-medicine-stock-sank-today/
Why Editas Medicine Stock Sank Today | The Motley Fool
Mar 4, 2021 - The stock was pulled down by the undertow of the broader market sell-off.
the motley fooleditas medicinestocksanktoday
https://www.ad-hoc-news.de/boerse/news/ueberblick/editas-medicine-inc-aktie-us28106w1036-quartalszahlen-im-fokus-und-wettbewerb-im-gentherapie-sektor/69549752
Editas Medicine Inc-Aktie (US28106W1036): Quartalszahlen im Fokus und Wettbewerb im Gentherapie-Sekt
Die Editas Medicine Inc-Aktie bleibt nach den jüngsten Quartalszahlen und im Vergleich zu Wettbewerbern im Gentherapie-Sektor im Fokus. Privatanleger blicken...
editas medicineim fokusincaktiequartalszahlen
https://lifesciencetracker.com/companies/editas-medicine/
Editas Medicine Archives - Incubate Investment Tracker
editas medicinearchivesincubateinvestmenttracker